Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness
Go back to Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 32.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.98 | 52 Week High | $18.62 | |||
| Open | $32.98 | 52 Week Low | $2.85 | |||
| Day High | $32.98 | P/E | N/A | |||
| Day Low | $32.98 | EPS | $-1.02 | |||
| Volume | 717 | |||||
